[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,75,101,129,157,181,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100406386","pilot-study-for-thyroid-surgery-by-preoperative-video-support-and-personalized-and-secure-web-platform-100406386",false,"NCT04571736","Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform","Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP)","AMEDOP","Inclusion Criteria:\n\n* Age between 18 and 75,\n* Indication of lobo-isthmectomy or total thyroidectomy\n* Compliance for the completion of self-questionnaires\n* Person affiliated or beneficiary of a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Difficulty understanding the French language\n* Lack of internet access\n* Persons placed under the protection of justice,\n* Person under guardianship or curatorship\n* Person participating in another research including an exclusion period still in progress,\n* Subject with severely impaired physical and \u002F or psychological health, which, according to the investigator, may affect the compliance of the study participant\n* Pregnant \u002F lactating woman","ALL","18 Years","75 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25],"NA","The medical information delivered to the patient before any surgery constitutes an essential and compulsory step during the initial management of the operated patient.\n\nThere are different reasons for the quantity and quality of medical information retained by the patient. An internet platform with personalized and secure access has been developed. This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.\n\nThe investigators believe that unlimited access for the duration of the study to this platform could reduce the preoperative anxiety level of patients.",[28],"Thyroid",[30,31],"Preoperative Procedure","Instructional Films and Video","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2020-11-18",{"date":40,"type":22},"2027-03-18",{"name":42,"class":43},"University Hospital, Montpellier","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100495577","a-study-to-collect-information-about-the-use-of-redifferentiating-medications-as-a-standard-treatment-for-thyroid-cancer-100495577","NCT05733013","A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer","Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study","Inclusion Criteria:\n\n* Patients ≥ 18 years old at time of consent\n\nInclusion Criteria:\n\n* Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.\n* Patients who will receive redifferentiation agents prior to planned diagnostic and\u002For therapeutic use of radioactive iodine as part of routine clinical care.\n* Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and\u002For therapeutic radioactive iodine administration.\n* Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and\u002For therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.\n\nExclusion Criteria:\n\n* RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and\u002For therapeutic use of radioactive iodine as part of a prospective clinical trial.",{"count":53,"type":22},100,"100 Years","OBSERVATIONAL","The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine\u002FRAI-refractory thyroid cancer. This study is a registry study.",[58,28,59],"Thyroid Cancer","Refractory Thyroid Cancer",[61,62,63,59,64,65,66],"RAI refractory thyroid cancer","thyroid cancer","thyroid","Radio-iodine refractory thyroid cancer","22-320","Memorial Sloan Kettering Cancer Center","2026-04-22",{"date":69,"type":36},"2026-04-27",{"date":71,"type":36},"2023-02-07",{"date":73,"type":22},"2028-02-07",{"name":66,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100409784","correlation-vitamin-d-level-to-endocrine-autoimmune-toxicity-due-to-immune-checkpoint-inhibitors-100409784","NCT04615988","Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","Correlation of Serum Vitamin D Level With the Development of Endocrine Autoimmune Complications During Treatment With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Malignancy which the treating oncologist plans for next treatment to inhibit PD-1or PD-L1 with the immune inhibitor being the only immunotherapy. Twenty-five subjects in a separate cohort will need for eligibility to be planned for treatment with anti-PD1\u002FPD-L1 plus antri-CTLA-4 therapy.\n* Willingness to complete symptom questionnaires\n* Willingness to allow blood draws\n* Ability to provide informed consent\n* Age \\> 18 years old\n\nExclusion Criteria:\n\n* History of clinical or subclinical hyperthyroidism or hypothyroidism\n* Hemoglobin \\\u003C 9\n* Inability to come for all study visits.\n* Actively on vitamin D supplementation due to vitamin D deficiency (As part of a multivitamin is not exclusionary)\n* Pregnant or lactating\n* History of hypophysitis",{"count":83,"type":22},17,"The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed death ligand-1 (PD-L1). Immunotherapy is treatment that makes changes to the immune system to try to fight cancer. Immunotherapy treatments that block the activity of important parts of the immune system called PD-1 and PD-L1 are used to standardly treat many different types of cancer and can cause thyroid toxicity in certain people. In this study the treatment for your cancer is not research treatment but standard of care determined by your oncologist. Blood will be drawn before starting treatment to determine the amount of Vitamin D and also to assess thyroid function. Also questionnaires will be completed before starting treatment and while on treatment to assess symptoms you are experiencing.",[28,86,87],"PD-1","Cancer",[89,90,91],"vitamin D deficiency","immunotherapy with inhibitor of PD-1\u002FL1","immune mediated thyroid toxicity","2026-03-23",{"date":94,"type":36},"2026-03-27",{"date":96,"type":36},"2021-06-09",{"date":98,"type":22},"2028-06",{"name":100,"class":43},"Icahn School of Medicine at Mount Sinai",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100551075","patient-centered-dosage-of-levothyroxine-100551075","NCT06455371","Patient-centered Dosage of Levothyroxine","Patient-centered Decision Support Tool for Levothyroxine Dosage","Inclusion Criteria:\n\n* Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals\n\nExclusion Criteria:\n\n* Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy",{"count":109,"type":22},240,[25],"Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.",[113,58,28],"Hypothyroidism",[115,116,117,118],"Decision support tool","Patient-centered dosage","thyroidectomy","levothyroxine","2025-09-03",{"date":121,"type":36},"2025-09-10",{"date":123,"type":36},"2024-12-20",{"date":125,"type":22},"2027-12",{"name":127,"class":43},"University Hospital of North Norway",3,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":55,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100529786","descripitive-patient-analysis-to-enable-risk-based-quality-improvement-measures-in-a-large-internal-medicine-group-practice-100529786","NCT06178302","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice","DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice - The EMANCIPATE Study","EMANCIPATE","1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site.",{"count":138,"type":22},1000,"10 Years","Background: Clinical trials often include patients from large hospitals or university clinics. Information on patients cared for at offices from statutory health insurance-accredited physicians represent evidence gaps.\n\nAims\u002FObjectives:\n\nThe present study has three aims: First, to systematically describe the patient population of a large group practice for internal medicine. Second, to identify high-risk patients using established risk scores. And third, to include routine imaging data to optimize patient management.\n\nMethods\u002FFacility Enrolling Participants: This is a prospective, observational study assessing patients' baseline characteristics, risk evaluation and integrating data from imaging test. The setting of the present study is a large group practice for internal medicine which consists of statutory health insurance-accredited physicians. Study participants will be included during daily routine, real-world clinical care and therefore represent all-comers fulfilling the inclusion criteria:\n\n1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.\n2. Routine laboratory results available within the last 3 months.\n3. Available imaging data within the last 3 months performed on site. Perspective: The study is designed to evaluate the current situation and quality of health care in defined patient populations in the routine clinical setting of a large-scale public office. These data will provide a profound rationale to identify quality issues and limitations in our performance of guideline-conform treatment in routine patient care.",[142,28,143,144,145,146],"Liver Dysfunction","Atherosclerosis","Heart Failure","Intestinal Disease","Heart Diseases","NOT_YET_RECRUITING","2025-05-05",{"date":150,"type":36},"2025-05-07",{"date":152,"type":22},"2025-12",{"date":154,"type":22},"2035-06",{"name":156,"class":43},"Imed19",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":166,"studyType":55,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100309517","intraoperative-monitoring-to-predict-postoperative-complications-after-thyroidectomy-100309517","NCT03309384","Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy","Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy","PARACAL","Inclusion Criteria:\n\n* patients scheduled for total thyroidectomy in university of Nancy (University Hospital)\n\nExclusion Criteria:\n\n* refusal to participate",{"count":138,"type":22},"1 Year","The goal of this study is to evaluate the role of intraoperative continous and intermittent neuromonitoring and intraoperative parathormone (PTH) to predict postoperative nerve morbidity and hypocalcemia.",[169,28,170,171],"Endocrine Procedural Complications","Parathyroid; Deficiency","Laryngeal Injury","2025-02-11",{"date":174,"type":36},"2025-02-12",{"date":176,"type":4},"2016-03-20",{"date":178,"type":22},"2026-03-20",{"name":180,"class":43},"Central Hospital, Nancy, France",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":44},"100577606","a-study-of-online-follow-up-in-patients-with-papillary-thyroid-cancer-100577606","NCT06800482","A Study of Online Follow-up in Patients With Papillary Thyroid Cancer","A Randomized Controlled Study of Online Outpatient Follow-up in Patients With Papillary Thyroid Cancer After Surgery","Inclusion Criteria：\n\n* clinical diagnosis of papillary thyroid cancer\n* has underwent thyroid surgery (including endoscopic and open thyroid surgery)\n* 18 to 90 years of age\n* spoke Chinese\n* has the ability to use mobile phones and the Internet to complete the visit\n* voluntarily participate in clinical trials and sign informed consent.\n\nExclusion Criteria：\n\n* postoperative hospital stay more than 5 days\n* inability to complete an online visit (no access to the device or the Internet\n* high risk of postoperative complications (recurrent laryngeal nerve injury, etc.)\n* unable to participate due to comorbidities, laboratory test results or physical disability\n* pregnancy\n* has mental illness or take psychotropic drugs, and were not able to perform the surgery",true,"90 Years",{"count":191,"type":22},388,[25],"The randomized, actively controlled, non-inferiority trial is scheduled to begin in August 2024 and run through August 2026. Inclusion criteria: (1) has undergone microwave ablation of thyroid or thyroidectomy (including endoscopy and opening) at the Department of Thyroid Surgery of West China Hospital of Sichuan University, (2) is between 18 and 90 years old, (3) speaks Chinese, (4) has the email address and operational ability required to complete the visit, (5) does not have a mental illness or take psychotropic drugs, (6) Voluntarily participate in clinical trials and sign informed consent. Exclusion criteria: (1) postoperative hospital stay more than 3 days; (2) Inability to complete an online visit (no access to the device or the Internet); (3) High risk of postoperative complications (recurrent laryngeal nerve injury, etc.); (4) Inability to participate due to a medical condition, laboratory test results, or physical disability (as determined by the principal investigator or surgeon).\n\nThe online outpatient follow-up was completed by thyroid surgeons of West China Hospital. Informed consent signed with a voluntary participant after a research team member contacts the patient and introduces the patient to the study. The investigators who contacted, enrolled, and randomly assigned patients included the principal investigator, the study coordinator, and the research assistant who had been specially trained in the study.\n\nAccording to the agreement, the participants randomly assigned to online visits will cross over with offline visits and withdraw from the clinical trial if :(1) unresolved technical issues, (2) inability to perform a full evaluation, (3) need\u002Frequest prescription painkillers, and (4) additional care recommended by a physician. Other cross-cutting reasons include patient requests and scheduling conflicts.\n\nThe information department of WestChina hospital obtained online and offline participants' demographic data and comorbidities, related information of chief complaint (including time of illness, information of last visit, drugs being used, contents of consultation, disease symptoms, conclusions of consultation, etc.), and online and offline outpatient information (including application time, reception time, patient satisfaction, etc.). Whether to prescribe medicine, whether to prescribe examination\u002Fadmission certificate, outpatient cost, number of questions, number of return visits, etc.) Employment, living conditions and the highest education level were obtained through the questionnaire survey at the time of enrollment, and the information about participant experience and satisfaction was obtained through the questionnaire survey after follow-up. The investigators recorded the diagnosis and treatment details of the patients at three online\u002Foffline follow-up visits at 1, 3, and 6 months after surgery. The investigators reviewed the electronic medical record 30 days after the last follow-up to monitor for adverse events. Participants were surveyed by email 30 days after the last follow-up to assess adverse events, including readmissions. If the survey is not answered within a week, an electronic reminder is sent and two attempts are made to contact the participants by phone.",[28,195],"Papillary Thyroid Cancer",[197,198,199],"Papillary thyroid cancer","surgery","out-patient","2025-01-28",{"date":202,"type":36},"2025-01-30",{"date":204,"type":36},"2024-08-07",{"date":206,"type":22},"2026-10-07",{"name":208,"class":43},"West China Hospital",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":219,"studyType":55,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":44},"100427427","a-prospective-single-arm-multi-centre-blinded-observational-diagnostic-accuracy-study-with-a-diagnostic-medical-product-100427427","NCT04845867","A Prospective, Single-arm, Multi-centre, Blinded, Observational, Diagnostic Accuracy Study With a Diagnostic Medical Product","Thyroid HEmorrhage DetectOr Study","HEDOS","Inclusion Criteria:\n\n* Age ≥18 years.\n* Indication for thyroid surgery (e.g. total thyroidectomy, subtotal resection, partial resection or lobectomy) in routine clinical care according to applicable medical guidelines using all adequate surgical approaches.\n* Signed informed consent\n\nExclusion Criteria:\n\n\\- Intended use of drains",{"count":218,"type":22},1470,"1 Month","After thyroid surgery, 0.6 to 4% of patients develop postoperative bleeding. 90% of this postoperative bleeding occurs within the first 48 hours. Most of the time, the complications are rapidly progressing and require immediate attention. Up to 0.6% of patients with postoperative bleeding die. In a clinical study with postoperative pressure measurements it could be shown that postoperative bleeding without interruption leads to a continuous increase in pressure in the neck, as is observed when coughing and pressing. Systematic invasive pressure measurement in the thyroid compartment after surgery might detect a continuous increase in pressure which is often caused by a growing haematoma, indicating serious post-surgery bleeding at a much earlier time compared to state of the art diagnostic workflow. n routine clinical care, detection of serious haemorrhage depends on the patients alerting symptoms even if post-operative intermittent monitoring of vital parameters and wound conditions is performed according to current medical guidelines and local instructions. Device-based, continuous haemorrhage detection within 36 to 48 hours after surgery would allow to objectively measure an increase in cervical pressure before symptoms occur, i.e. early detection of risk leading to timely therapeutic actions. Thus, the risk of serious complications like hypoxic brain damage and death caused by post-operative haemorrhage is minimized. In addition, the intervention team would be able to fine-tune necessary actions during the rescue procedure based on objective pressure values, e.g. the decision to open cutaneous sutures immediately or later in the operation theatre, and therefore reduce additional perioperative morbidity and increase patients' safety.",[28],"2024-07-05",{"date":224,"type":36},"2024-07-08",{"date":226,"type":36},"2023-10-23",{"date":228,"type":22},"2024-11-24",{"name":230,"class":231},"ISAR-M GmbH","INDUSTRY"]